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Background: Pulmonary rehabilitation (PR) is recognized as an evidence-based treatment in 
improving dyspnea and quality of life in patients with COPD. We evaluated the number needed 
to treat (NNT) to achieve an increase in physical capacity, as defined by a significant improvement 
in the six-minute walk test (6MWT) in patients with COPD undergoing PR.
Methods: The study enrolled 284 patients aged 41 to 86 years (mean age 69.4 years) divided 
into two groups: a study group (222 patients) undergoing a PR program, and a control group 
(62 patients) treated only with drugs. The study group included patients with COPD divided 
in four subgroups according to GOLD stages.
Results: In the study group, 142 out of 222 patients (64%) had an increase of at least 54 m 
in the 6MWT following PR versus 8 out of 62 patients (13%) in the control group after the 
same time interval. The NNT in the overall study group was 2; the same NNT was obtained 
in GOLD stages 2, 3, and 4, but was 8 in stage 1.
Conclusions: PR is highly effective in improving the exercise capacity of patients with 
COPD, as demonstrated by a valuable NNT, with better results in patients with a more severe 
disease.
Keywords: chronic obstructive lung disease, exercise capacity, number needed to treat, 
pulmonary rehabilitation, six-minute walk test
Introduction
Chronic obstructive pulmonary disease (COPD) causes progressive impairment of 
airflow and physical capacity.1 Measurement of lung function currently establishes 
the severity of the disease,1 while exercise capacity is associated with health-related 
quality of life.2,3 Both functions define the health status in COPD patients and their 
deterioration is implicated in a decrease of life expectancy,1,4,5 with a more strict 
association reported for physical disability than for lung function.4,6 An accepted 
method to measure exercise capacity is the walk test, which was initially introduced 
as the distance walked in 12 minutes,7 but was later developed and standardized as 
the six-minute walk test (6MWT).8
Pulmonary rehabilitation (PR) is an evidence-based standard of care for COPD 
patients, recently reviewed in a consensus document.9 In this document the statement 
“A program of exercise training of the muscles of ambulation is recommended as a 
mandatory component of PR for patients with COPD” is given a 1A grade of recom-
mendation.9 In assessing the effects of PR on physical performance, the 6MWT test was 
demonstrated to be an adequate index10 and the cut-off indicating significant improve-
ment was established in an increase of 54 m in respect to the baseline value.11International Journal of COPD 2009:4 316
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This study aimed to analyze the number needed to treat 
(NNT), that is, the number of patients who need to be treated 
in order to have one patient with clinically significant benefit, 
to evaluate the improvement in exercise capacity, as defined 
by an increase of at least 54 m in the distance walked during 
the 6MWT in patients with COPD undergoing PR.
Methods
Patients
The study enrolled 291 patients, however seven did not 
take part due to family problems (three cases), moving (one 
case), or personal unspecified reasons (three cases). The 
study population consisted of 284 patients aged between 
41 and 86 years (185 males, 122 females, mean age 69.4, 
standard deviation [SD] 8.3 years). All subjects gave 
formal consent and the study was approved by the Hospital 
Ethics Committee. Study subjects were categorized into 
two groups. The study group was defined as group A. 
This group was made up of 222 patients aged between 
41 and 86 years (149 males, 96 females, mean age 69.2, SD 
8.6 years) referred between January and December 2006 to 
the Pulmonary Rehabilitation Unit of the Istituti Clinici di 
Perfezionamento of Milan, all undergoing a six-week PR 
program. The study group included patients with COPD 
and was divided in four subgroups according to the Global 
Initiative for chronic Lung Disease (GOLD) stages, based 
on forced expiratory volume in one second (FEV1) values;1 
group 1 comprised patients with FEV1 not lower than 80%, 
group 2 patients with FEV1 between 80% and 50%, group 
3 patients with FEV1 between 50% and 30%, and group 4 
patients with FEV1 values lower than 30%.
The control group was defined as group B, consisting 
of 62 patients aged between 43 and 81 years (36 males, 
26 females, mean age 70.3, SD 7.6 years) treated only with 
pharmacological therapy without any kind of PR. This group 
included patients for whom PR was planned in subsequent 
months. They were asked to repeat the 6MWT after six weeks 
so to have the same time-interval as the study group. In both 
study and control groups the drug treatment by bronchodila-
tors and, when needed, inhaled corticosteroids was adjusted 
to optimal dosage and inhalation technique.
Pulmonary rehabilitation
The program was conducted following a schedule of 
12 visits in a six-week period in a day hospital setting. 
Subjects followed an exercise program using either a cycle 
ergometer or treadmill, according to the patient’s capacity, 
for 30 minutes; upper-limb and trunk exercise training, with 
warm-up and limbering exercises focusing on arm, shoulder 
and trunk muscle groups for 30 minutes; and respiratory 
muscle training done by low pressure peak expiratory pressure 
(PEP) using a bottle at 6–8 cm H2O with a 80-cm long, 1-cm 
wide tube, again for 30 minutes. In addition, patients attended 
a standard COPD education course, and were taught how to 
perform muscle exercises and respiratory training every day 
at home for the entire duration of the program.
Six-minute walk test
The 6MWT was conducted according to American Thoracic 
Society (ATS) guidelines8 and supervised by qualified 
technicians, who were not told which group each patient 
belonged to. In brief, each patient was instructed to walk 
at his or her own pace along a straight, flat 27 m hospital 
corridor marked at both extremities. Heart rate, blood 
pressure, oxygen saturation, and Borg score (based on an 
exertion scale where 0 = no exertion and 10 = very severe 
exertion) were measured at the start (0 min) and at the end 
(six minutes) of the walk test. Patients were asked to cover 
as much ground as possible in six minutes but were allowed 
to stop if they showed symptoms of dyspnea or leg pain. The 
distance in meters was recorded at the end of the six minutes. 
The 6MWT was performed immediately before and after 
PR in the study group and with the same time interval 
(six weeks) in the control group.
Statistical analysis
The effectiveness of PR in inducing an improvement of at 
least 54 m with the 6MWT was analyzed by the NNT, which 
is a treatment-specific measurement and demonstrates the 
difference between treatment and control in achieving a 
particular outcome. According to its original formulation,12 
NNT is calculated as the inverse of the absolute risk reduction 
(ARR), where ARR = control event rate - experimental event 
rate. NNT value and confidence intervals (CI) for the overall 
group of patients undergoing PR and for single subgroups 
defined by COPD severity was analyzed using GraphPad 
Prism (Graph Pad Software Inc., San Diego, CA, USA).
The rate of patients obtaining the 54-m increase in the 
different groups was compared by the chi-squared test, setting 
the significance at p  0.05.
Results
Table 1 reports the main characteristics of patients at baseline. 
Considering all patients of group A, 142 out of 222 (64%) 
had an increase of at least 54 m in the 6MWT following PR. International Journal of COPD 2009:4 317
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In group B, 8 out of 62 patients (12.9%) had an increase 
of 54 m in the 6MWT after the same time interval with 
no PR. This difference was significant (p  0.001) with 
the chi-squared test. In the study subjects, 36% did not 
achieve the significant increase, compared to 87.1% of the 
control subjects. The absolute risk reduction was 47.5% 
(95% CI: 37.1% to 57.9%). The NNT obtained was 2 (95% 
CI: 1.6 to 2.5).
The subgroups of patients in group A were formed as 
follows: group in GOLD stage 1, 37 patients (24 males, 
13 females, mean age 64.6 ± 9.8 years, range 41 to 83 years); 
group in GOLD stage 2, 95 patients (61 males, 34 females, 
mean age 72.7 ± 8 years, range 41 to 86 years); group in 
GOLD stage 3, 47 patients (29 males, 18 females, mean age 
67.6 ± 6.6. years, range 57 to 82 years); group in GOLD stage 
4, 43 patients (27 males, 16 females, mean age 68 ± 6.9 years, 
range 58 to 86). There were no significant differences in the 
distribution of males and females in the different groups. 
Table 2 shows the results of the 6MWT and the NNT 
values in the subgroups of patients. The difference in the 
number of patients obtaining a 54-m increase versus control 
group was nonsignificant for group 1, but significant for 
groups 2, 3, and 4, with a p value  0.001 in each group.
Discussion
The impairment of exercise capacity in patients with COPD is 
a central issue in the natural history of this disease.1 A recent 
study reported that in more severe GOLD stages of COPD 
there is an higher decrease in exercise capacity than in FEV1 
predicted values,13 which however remains the parameter 
classifying the severity of COPD.1 The six-minute walk 
distance (6MWD) is an accepted method to measure exercise 
capacity,8 which was also recently validated by mathematical 
models.5 By such test, an increase of 54 m from the baseline 
value is considered a significant improvement in physical 
capacity.11
PR is a valuable treatment for COPD patients.14,15 The 
evidence-based clinical practice guidelines by the Joint 
Commission of the American College of Chest Physi-
cians (ACCP) and the American Association of Cardio-
vascular and Pulmonary Rehabilitation (AACVPR) stated 
25 evidence-based recommendations.9 These statements 
include the capacity of PR to improve the symptoms of 
dyspnea (grade 1A) and the health-related quality of life 
(grade 1A), but no statement concerns the improvement of 
physical capacity. In fact, studies on this particular issue 
reported different observations: in 1999 a meta-analysis 
detected a significant improvement in the 6MWD after PR, 
corresponding to a mean value of 49 m;16 in a more recent 
Cochrane systematic review, which included 16 trials, a very 
similar but not significant increase of 48 m was found.17 
In any case, both values were below the threshold of clinical 
significance, ie, the 54 m increase.
In the present study, considering the overall population 
of patients undergoing PR, the mean distances walked 
before and after PR were 296.8 m and 384.7 m, respectively, 
corresponding to a mean increase of 87.9 m, which is above 
the threshold of clinical significance. The lesser heterogeneity 
of our patients in respect to the meta-analyses, which included 
different studies, may account for such a finding. Analyzing 
the difference according to COPD severity, stage 1 of disease 
had the lower increase (63 m), while the increase in walked 
distance was 68.5 m for stage 2, 89.1 m for stage 3, and 
132 m for stage 4. It has been reported that females have a 
higher 6MWD,5 which could possibly influence the results of 
global analyses, but in our groups there were no significant 
Table 1 Main characteristics of patients at baseline
Group 
 
FEV1 in mL 
(%)
SGRQ 
Total score
Meters walked 
during 6MWT
Study group 1219 ± 465
(54.4 ± 20.7)
53.6 ± 15.6 296.8 ± 88.7
Control group
  
1267 ± 513
(53.8 ± 13.2)
51.9 ± 18.8
 
301.2 ± 67.8
 
Abbreviations: FeV1, forced expiratory volume at one second; SgRQ, St. george’s 
Respiratory Questionnaire; 6MWT, six-minute walk test.
Table 2 nnT in the subgroups of different gOLD stages
Subgroup  Meters walked before  
PR (mean ± SD)
Meters walked after  
PR (mean ± SD)
No of patients with  
a 54 m increase
NNT  95% CI 
gOLD 1 355 ± 63 418 ± 78 10/37 8 -2.4 to 30.7
gOLD 2 324.8 ± 102.3 393.3 ± 82.5 60/95 2 1.6 to 2.7
gOLD 3 327.4 ± 117.1 416.5 ± 102.7 33/47 2 1.4 to 2.4
gOLD 4  180 ± 60.7 312 ± 81.1 39/43 2 1.1 to 2.5
Abbreviations: CI, confidence interval; GOLD, Global Initiative for Chronic Obstructive Pulmonary Disease; NNT, number needed to treat; PR, pulmonary rehabilitation; 
SD, standard deviation.International Journal of COPD 2009:4 318
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differences in the distribution of females in the different 
groups. However, the aim of the study was to evaluate by 
NNT the effectiveness of PR in improving the physical 
capacity in COPD patients. This statistical analysis was 
introduced in 1988 as a measure able to assess more precisely 
the consequences of a medical treatment,12 and was initially 
greeted with enthusiasm18 but was later the object of some 
criticism.19 In particular, when measuring the effectiveness 
of interventions targeting chronic diseases, NNT varies over 
time and thus does not capture the crucial time component.19 
For example, in analyzing the effectiveness of finasteride 
for the treatment of benign prostatic hyperplasia, the NNT 
for avoiding prostate-related surgery was 31 (21 to 61) over 
24 months but was 18 (14 to 27) over 48 months.20
In our study the time bias was not present as the NNT was 
calculated after the first cycle of PR, the only point when the 
comparison with baseline values can be made. Subsequent 
cycles generally maintain improved exercise capacity,21–23 but 
further increases over the threshold of clinical significance 
are not expected.
Some studies have used the NNT to evaluate the outcome 
of pulmonary rehabilitation in COPD patients: a recent 
meta-analysis of six trials which included 219 patients 
undergoing PR after exacerbations of COPD found a NNT 
of 3 in reducing subsequent hospital admissions and of 
6 in reducing mortality.24 In a Canadian study, NNT was 
calculated by focusing on the quality of life assessed by the 
Chronic Respiratory Questionnaire (CRQ) and ranged from 
2.5 for mastery to 4.4 for fatigue.25 Regarding the 6MWT, the 
improvement is generally analyzed calculating the difference 
in the mean distance walked17 and only one study, to the 
best of our knowledge, analyzed the NNT.26 This particular 
study evaluated 34 patients with stable COPD receiving a 
PR program for six months versus 28 patients receiving 
usual medical care, and found a NNT of 3. The NNT 
obtained in the present study, including 222 patients versus 
62 controls, was 2. The different time intervals in the two 
studies – six months versus six weeks – is likely to account 
for the difference, taking into consideration that, in the study 
by Troosters and colleagues,26 the most intense training was 
done in the first three months.
Dividing the patients into the GOLD severity stages, we 
found a different result in patients with initial stage – NNT 
corresponding to 8 – compared to patients with advances 
stages, in whom the NNT was 2. We did not include the 
GOLD stage 0 in our analysis, which is considered in the 
initial classification of severity, but not in the last update of 
GOLD guidelines.27 The significance of the observation is 
that in mild stage of COPD, with a FEV1 value not lower 
than 80% of predicted, eight patients must be treated by PR 
to have one patient with a significant increase of exercise 
capacity. This confirms the current indication to apply PR in 
COPD patients starting from the GOLD stage 2.9
In conclusion, this study found that a PR program with 
physical training, upper-limb and trunk exercise training, and 
respiratory muscle training is highly effective in improving 
the exercise capacity of patients with COPD, as demonstrated 
by a NNT of 2.
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